Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
On August 14, 2026, the Company issued a press
release, a copy of which is attached to this Form 8-K as Exhibit 99, announcing results for the periods ended June 30, 2026.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Exhibit 99
RETRACTABLE TECHNOLOGIES, INC. RESULTS
FOR THE PERIODS ENDED JUNE 30, 2026
LITTLE ELM, TEXAS, August 14, 2026 —
Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.2 million for the second quarter of 2026 and an
operating loss of $5.1 million for the period, as compared to total net sales for the same period last year of $10.4 million and an operating
loss of $5.1 million. For the first half of the year, net sales were $14.4 million and operating losses were $11.3 million as compared
to 2025 net revenues of $18.7 million and operating losses of $9.8 million.
While the majority of flu season sales typically
occur in the third quarter, in 2025, purchasing patterns differed with unusually high unit sales related to flu season products in the
second quarter of 2025, impacting comparability to second quarter 2026 unit sales related to flu season products, which follows a more
traditional purchasing pattern.
Domestic production increased to 42.4% of the
units manufactured during the first six months of 2026 compared to 38% of units produced domestically for the first six months of 2025.
Additionally, as previously reported, a reduction in force in April 2026 is expected to result in cost savings in future periods.
Our net income (loss) for the three and six months
ended June 30, 2026 was $2.8 million and $(1.4) million, respectively, including a $6.4 million gain on the sale of equity securities
in the second quarter of 2026.
Comparison of Three Months Ended June 30,
2026 and June 30, 2025
Domestic sales accounted for 81.6% and 81.3% of
total revenues for the three months ended June 30, 2026 and 2025, respectively. Domestic revenues decreased 30.8%, while domestic
unit sales decreased 35.1%. Domestic unit sales represented 70.3% of total unit sales for the three months ended June 30, 2026 compared
to 68.9% for the same period last year. The decrease in sales and units was primarily due to the timing of EasyPoint® product
orders from certain customers, which can fluctuate between periods based on customer purchasing patterns.
International revenues for the three months ended
June 30, 2026 decreased 32.2% compared to the same period in 2025. The decrease in international sales was primarily driven by a
decrease in EasyPoint® needle sales. Traditionally, international sales carry lower average selling prices compared to
our domestic sales. There remains uncertainty regarding the timing of future international orders.
Overall, units sales decreased 36.4% due to a
decrease in EasyPoint® needle sales.
Cost of manufactured product decreased 34.7% compared
to the same period last year primarily due to a decrease in sales. Royalty expense decreased 20.8% due to the decrease in gross sales.
Tariffs may continue to materially impact our
costs in future periods. Approximately $46 thousand was spent on tariff expenses in the second quarter of 2026. The reduction in tariff
costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic
production. These costs are included in Cost of manufactured product.
Operating expenses remained consistent in the
three months ended June 30, 2026 and 2025.
The loss from operations was $5.1 million for
the three months ended June 30, 2026 and 2025.
The unrealized loss on debt securities was $179
thousand for the second quarter of 2026 due to the decreased market values of those securities. The realized gain from the sale of equity
was $6.4 million in the second quarter of 2026.
The provision for income taxes was $1.8 thousand
for the three months ended June 30, 2026 and 2025.
Comparison of Six Months Ended June 30,
2026 and June 30, 2025
Domestic sales accounted for 82.2% and 85.0% of
total revenues for the six months ended June 30, 2026 and 2025, respectively. Domestic revenues decreased 25.8%, while domestic unit
sales decreased 25.0%. Domestic unit sales represented 71.2% of total unit sales for the six months ended June 30, 2026 compared
to 74.9% for the same period last year. The decrease in sales was primarily due to a decrease in EasyPoint® needle unit
sales.
International revenues for the six months ended
June 30, 2026 decreased 9.3% compared to the same period in 2025. Traditionally, international sales carry lower average selling
prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.
Overall, units sales decreased 21%.
Cost of manufactured product decreased 20.8% compared
to the same period last year primarily due to a decrease in units sold. Royalty expense decreased 14.4% due to the decrease in gross sales.
Tariffs may continue to materially impact our
costs in future periods. Approximately $58 thousand was spent on tariff expenses in the first six months of 2026. The reduction in tariff
costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic
production. These costs are included in Cost of manufactured product.
Operating expenses increased 10.0% primarily due
to donation expense.
The loss from operations was $11.3 million compared
to a loss of approximately $9.8 million for the same period last year. The increase in loss from operations was primarily driven by a
decrease in revenue and increase in operating expenses due to donation expense.
The unrealized gain on debt securities was $13
thousand for the six months ended June 30, 2026 due to the increased market values of those securities. The realized gain from the
sale of equity was $6.4 million in the first six months of 2026.
The provision for income taxes was $3.7 thousand
as compared to a benefit for income taxes of $288 thousand for the same period in 2025. The change is primarily due to a decrease in the
net loss in the current period.
ABOUT RETRACTABLE
Retractable manufactures and markets VanishPoint®
and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint®
needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
line distributors.
For more information on Retractable, visit its
website at www.retractable.com.
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
such statements.
Factors that could cause or contribute to such
differences include, but are not limited to: tariffs; material changes in demand; Retractable's ability to maintain liquidity; Retractable's
maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and
relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in
providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief
Accounting Officer
